Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
19 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Chu de Nantes - Hôtel-Dieu
Nantes, France
Recruiting - Hôpital Robert Debré - Service D'Hémato-Immunologie
Paris, France
Recruiting - Hôpital Saint Louis, Unité D'Hématologie Adolescents Et Jeunes Adultes Département D'Hématologie
Paris, France
Recruiting - Hôpital Lyon Sud
Pierre-Bénite, France
Recruiting - Chu Rennes - Hopital Pontchaillou
Rennes, France
Recruiting
- University of California, Los Angeles (ucla) - Medical Center
Los Angeles, California, United States
Recruiting - University of Colorado - Aurora Cancer Center
Aurora, Colorado, United States
Recruiting - Sarah Cannon - Colorado Blood Cancer Institute
Denver, Colorado, United States
Recruiting - University of Chicago
Chicago, Illinois, United States
Recruiting - Dana Farber Cancer Institute
Boston, Massachusetts, United States
Recruiting - Roswell Park Comprehensive Cancer Center
Buffalo, New York, United States
Recruiting - Memorial Sloan Kettering Cancer Center (mskcc) David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
New York, New York, United States
Recruiting - Weill Medical College of Cornell University
New York, New York, United States
Withdrawn - Children'S Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Recruiting - Sarah Cannon - Hca Research Institute
Nashville, Tennessee, United States
Recruiting - Sarah Cannon - St. David'S South Austin Medical Center
Austin, Texas, United States
Recruiting - Md Anderson Cancer Center
Houston, Texas, United States
Recruiting - Sarah Cannon - Texas Transplant Institute at Methodist Hospital
San Antonio, Texas, United States
Recruiting - University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, United States
Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 14 Oct 2019
- Primary completion
- 30 Jun 2026
- Completion
- 30 Jun 2026
- Last update posted
- 9 Sept 2025
- Registered enrollment
- 52
- Registry id
- NCT04150497
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.